To compare real world characteristics and efficacy of Peginterferon Beta-1A with other platform injectable therapies in patients with multiple sclerosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Peginterferon beta-1a (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1a; Interferon beta-1b
Indications Multiple sclerosis
Focus Therapeutic Use

14 Nov 2018 Results assessing the relapse rates (n=1864) and relapse-related hospitalisation (n=1724) in RRMS patients treated with peginterferon beta-1a and other injectable therapies, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
19 Oct 2017 New trial record
12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com